Scott Lippman

Q: What Schools Are Affiliated With Scott Lippman

Scott Lippman is affiliated with the following schools: University of Oslo, MD Anderson Cancer Center, Louisiana State University, University of California, San Diego, Wayne State University, University of California, San Francisco, Seoul National University, McGill University, University of Milan, James Cook University, Vanderbilt University, Case Western Reserve University, Johns Hopkins University, Queen Mary University of London, University of Texas Southwestern Medical Center

Scott Lippman's AcademicInfluence.com Rankings

Scott Lippman

Philosophy

#3762

World Rank

#6025

Historical Rank

Logic

#1384

World Rank

#2126

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Scott Lippman's Degrees

Doctorate Medicine University of California, San Francisco
PhD Cancer Biology University of California, San Diego

Why Is Scott Lippman Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Scott M. Lippman is the former Director of Moores Cancer Center at the University of California, San Diego and current Professor of Medicine at UC San Diego School of Medicine. His clinical and translational research addresses head and neck and lung cancer, cancer genetics, predictive cancer biomarkers, and molecular targeting for cancer treatment.

(See a Problem?)

Scott Lippman's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Comprehensive genomic characterization of head and neck squamous cell carcinomas (2015) (2860)
The influence of finasteride on the development of prostate cancer. (2003) (2636)
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. (2004) (2473)
The Molecular Taxonomy of Primary Prostate Cancer (2015) (2116)
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2009) (2033)
Lung cancer. (2008) (1699)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. (2006) (1594)
Head and Neck Cancer (1993) (1386)
Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. (1990) (1381)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial (2008) (1275)
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2011) (999)
The BATTLE trial: personalizing therapy for lung cancer. (2011) (810)
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance (2012) (799)
Statins and cancer prevention (2005) (777)
Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy (2012) (703)
Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. (2005) (577)
Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment (1996) (525)
Clonal genetic alterations in the lungs of current and former smokers. (1997) (493)
Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC) (2010) (477)
Predicting cancer development in oral leukoplakia: ten years of translational research. (2000) (465)
Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. (1995) (463)
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. (2001) (436)
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. (2012) (413)
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. (2012) (411)
Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. (2005) (401)
Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. (1993) (397)
Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. (1998) (385)
Mortality risk from squamous cell skin cancer. (2005) (369)
Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. (2017) (368)
Obesity, Diabetes, and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial (2006) (359)
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2005) (352)
Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia (2002) (339)
Retinoids as preventive and therapeutic anticancer agents (Part I). (1987) (333)
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study (2019) (333)
13-cis-Retinoic Acid and Interferon α -2a: Effective Combination. Therapy for Advanced Squamous Cell Carcinoma of the Skin (1992) (326)
An integrin β3–KRAS–RalB complex drives tumour stemness and resistance to EGFR inhibition (2014) (307)
Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. (1989) (296)
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. (2006) (296)
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. (2001) (294)
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. (2013) (283)
Lipoxygenase modulation to reverse carcinogenesis. (2001) (275)
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer—A Plan to Move Forward (2006) (272)
13-cis-Retinoic Acid Plus Interferon α -2a: Highly Active Systemic Theraphy for Squamous Cell Carcinoma of the Cervix (1992) (269)
Lymph Node Metastases from Cutaneous Squamous Cell Carcinoma of the Head and Neck (2005) (267)
Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. (1995) (263)
Cancer chemoprevention. (1995) (259)
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. (2007) (253)
The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. (2001) (253)
SELECT: THE NEXT PROSTATE CANCER PREVENTION TRIAL (2001) (246)
Comprehensive Analysis of the MYB-NFIB Gene Fusion in Salivary Adenoid Cystic Carcinoma: Incidence, Variability, and Clinicopathologic Significance (2010) (244)
The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-δ to induce apoptosis in colorectal cancer cells (2003) (238)
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. (2002) (234)
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk. (2014) (231)
Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. (1994) (230)
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. (2010) (229)
Whole exome sequencing of adenoid cystic carcinoma. (2013) (226)
Randomized placebo-controlled trial of isotretinoin in chemoprevention of bronchial squamous metaplasia. (1994) (225)
Selenium effects on prostate cell growth. (2000) (214)
Molecular markers of the risk of oral cancer. (2001) (213)
Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial (2014) (212)
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. (2008) (207)
Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. (1994) (200)
15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. (2000) (191)
p53 Expression: Predicting Recurrence and Second Primary Tumors in Head and Neck Squamous Cell Carcinoma (1996) (189)
Frequent inactivation of p16INK4a in oral premalignant lesions (1997) (188)
Oral cancer prevention and the evolution of molecular-targeted drug development. (2005) (185)
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors (2018) (184)
Epithelial to mesenchymal transition in head and neck squamous carcinoma (2008) (181)
15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells. (2000) (177)
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. (2006) (174)
Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. (1998) (169)
Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67 (1988) (167)
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. (2009) (161)
Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis. (1997) (160)
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. (2010) (158)
Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. (2014) (154)
Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. (1999) (153)
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. (2005) (151)
Retinoids as preventive and therapeutic anticancer agents (Part II). (1987) (148)
SELECT: the selenium and vitamin E cancer prevention trial. (2003) (147)
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. (2003) (146)
Regression of oral leukoplakia with alpha-tocopherol: a community clinical oncology program chemoprevention study. (1993) (145)
The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype. (1988) (144)
Molecular targets for cancer chemoprevention (2009) (139)
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. (2015) (139)
Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. (1996) (138)
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. (2013) (137)
The Selenium and Vitamin E Cancer Prevention Trial (2003) (135)
Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. (1997) (135)
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy (2019) (135)
p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. (2003) (135)
Hypermethylation of the Retinoic Acid Receptor-β2 Gene in Head and Neck Carcinogenesis (2004) (132)
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. (2002) (131)
Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. (1999) (129)
Cancer chemoprevention: progress and promise. (1998) (128)
Differential expression of cyclooxygenase-2 and its regulation by tumor necrosis factor-alpha in normal and malignant prostate cells. (2001) (128)
Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. (1987) (128)
Novel Chromosomal Rearrangements and Break Points at the t(6;9) in Salivary Adenoid Cystic Carcinoma: Association with MYB–NFIB Chimeric Fusion, MYB Expression, and Clinical Outcome (2011) (128)
Transforming Cancer Prevention through Precision Medicine and Immune-oncology (2016) (128)
Future cancer research priorities in the USA: a Lancet Oncology Commission. (2017) (125)
N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. (2000) (125)
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy (2020) (122)
Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. (1999) (119)
Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. (2009) (119)
Positive Surgical Margins in the 10 Most Common Solid Cancers (2018) (117)
The risk of second primary tumors after resection of stage I nonsmall cell lung cancer. (2003) (117)
The influence of resection and aneuploidy on mortality in oral leukoplakia. (2004) (117)
The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease. (2001) (117)
Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917 (2011) (116)
Molecular epidemiology and retinoid chemoprevention of head and neck cancer. (1997) (115)
Loss of retinoic acid receptor-beta expression is an early event during esophageal carcinogenesis. (1999) (115)
Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention. (2005) (114)
Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. (1996) (114)
The Conundrum of Genetic “Drivers” in Benign Conditions (2016) (114)
Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss (2014) (113)
Cancer prevention: from 1727 to milestones of the past 100 years. (2009) (112)
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. (1998) (112)
Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. (1996) (111)
SELECT: the Selenium and Vitamin E Cancer Prevention Trial: rationale and design (2000) (110)
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. (2016) (110)
Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. (2001) (109)
Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer. (2019) (108)
Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer. (2017) (108)
Oxidative metabolism of linoleic acid modulates PPAR-beta/delta suppression of PPAR-gamma activity (2006) (107)
Genetic variation in MicroRNA genes and risk of oral premalignant lesions (2010) (105)
The cancer cell map initiative: defining the hallmark networks of cancer. (2015) (105)
Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. (2000) (105)
Cancer prevention science and practice. (2002) (103)
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. (2009) (103)
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. (2007) (102)
Expression and up-regulation of retinoic acid receptor-beta is associated with retinoid sensitivity and colony formation in esophageal cancer cell lines. (1999) (101)
HLA-DR (Ia) immune phenotype predicts outcome for patients with diffuse large cell lymphoma. (1988) (101)
Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonal antibody Ki-67. (1988) (101)
Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. (1997) (101)
13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. (1992) (100)
Assembly and activation of the Hippo signalome by FAT1 tumor suppressor (2018) (99)
Precancer Atlas to Drive Precision Prevention Trials. (2017) (98)
The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis. (2005) (97)
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. (2009) (96)
Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening. (2001) (96)
Randomized, Double-Blind, Placebo-Controlled Phase IIB Trial of the Cyclooxygenase Inhibitor Ketorolac as an Oral Rinse in Oropharyngeal Leukoplakia (2004) (94)
Pilot Randomized Phase II Study of Celecoxib in Oral Premalignant Lesions (2008) (94)
The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma: a study of calcitonin, L-dopa decarboxylase, and histaminase. (1982) (93)
Phase I evaluation of all-trans-retinoic acid in adults with solid tumors. (1993) (92)
Genetic Variants in Inflammation-Related Genes Are Associated with Radiation-Induced Toxicity Following Treatment for Non-Small Cell Lung Cancer (2010) (91)
Glycogen Synthase Kinase-3β Is Involved in the Phosphorylation and Suppression of Androgen Receptor Activity* (2004) (91)
Cancer chemoprevention. Part 1: Retinoids and carotenoids and other classic antioxidants. (1998) (91)
Nonsteroidal anti-inflammatory drugs induce apoptosis in esophageal cancer cells by restoring 15-lipoxygenase-1 expression. (2001) (91)
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597. (2013) (89)
Retinoic acid and interferon in human cancer: mechanistic and clinical studies. (1994) (89)
Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. (2000) (88)
Cyclic AMP response element-binding protein overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung cancer. (2008) (87)
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. (2007) (86)
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. (2007) (86)
Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine (2017) (86)
Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. (2013) (86)
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. (2009) (86)
Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. (2011) (86)
Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors (2014) (85)
Retinoids and chemoprevention: Clinical and basic studies (1995) (85)
Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary. (2017) (84)
Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single‐arm phase II clinical trial (2017) (84)
The incidence of second primary tumors in long-term survivors of small-cell lung cancer. (1992) (84)
Laryngeal preservation by induction chemotherapy plus radiotherapy in locally advanced head and neck cancer: The M. D. Anderson cancer center experience (1994) (82)
Nuclear retinoid acid receptor beta in bronchial epithelium of smokers before and during chemoprevention. (1999) (81)
13-cis-retinoic acid plus interferon-alpha 2a in locally advanced squamous cell carcinoma of the cervix. (1993) (81)
Squamous metaplasia of the bronchial mucosa and its relationship to smoking. (1993) (81)
Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT) (2004) (80)
Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. (2000) (79)
p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. (1996) (79)
Cancer Prevention: Obstacles, Challenges and the Road Ahead. (2016) (79)
Alleviating the Suppression of Glycogen Synthase Kinase-3β by Akt Leads to the Phosphorylation of cAMP-response Element-binding Protein and Its Transactivation in Intact Cell Nuclei* (2003) (79)
Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. (2000) (79)
Second international cancer chemoprevention conference. (1994) (78)
Prevention of prostate cancer with finasteride: US/European perspective. (2003) (77)
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. (2009) (77)
Feasibility of Image-Guided Transthoracic Core-Needle Biopsy in the BATTLE Lung Trial (2013) (77)
Autoimmune hemolytic anemia with reticulocytopenia and erythroid marrow. (1982) (76)
Second‐look laparotomy in epithelial ovarian carcinoma. Prognostic factors associated with survival duration (1988) (76)
Molecular signatures of lung cancer--toward personalized therapy. (2007) (76)
Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer (2012) (76)
Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. (2005) (76)
Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast. (2003) (75)
Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. (2007) (75)
Precision oncology: the UC San Diego Moores Cancer Center PREDICT experience. (2015) (74)
Tamoxifen prevention of breast cancer: an instance of the fingerpost. (1999) (74)
SELECT: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. (2001) (74)
Recent advances in head and neck cancer--larynx preservation and cancer chemoprevention: the Seventeenth Annual Richard and Hinda Rosenthal Foundation Award Lecture. (1993) (73)
Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. (2003) (73)
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial. (2021) (72)
Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma (2001) (71)
Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology (2017) (71)
Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. (1987) (71)
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. (1998) (71)
Progressive decreases in nuclear retinoid receptors during skin squamous carcinogenesis. (2001) (70)
Single nucleotide differences (SNDs) in the dbSNP database may lead to errors in genotyping and haplotyping studies (2010) (70)
Chemoprevention of breast cancer (2000) (70)
Detection of chromosomal polysomy in oral leukoplakia, a premalignant lesion. (1993) (69)
Lethal midline granuloma with a novel T‐Cell phenotype as found in peripheral T‐Cell lymphoma (1987) (69)
Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience (2016) (69)
The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Apoptosis via Induction of 15-Lipoxygenase-1 in Colorectal Cancer Cells (2004) (69)
Advances in the biology of lung cancer chemoprevention. (2005) (69)
The transcription factor GATA‐6 is overexpressed in vivo and contributes to silencing 15‐LOX‐1 in vitro in human colon cancer (2007) (68)
13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. (1992) (68)
Genetic factors predisposing to autoimmune diseases. Autoimmune hemolytic anemia, chronic thrombocytopenic purpura, and systemic lupus erythematosus. (1982) (68)
Impact of a peer-delivered telephone intervention for women experiencing a breast cancer recurrence. (2007) (67)
Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma (2018) (67)
Her-2/neu gene amplification in ductal carcinoma in situ of the breast. (2002) (66)
Induction of retinoic acid receptor-β suppresses cyclooxygenase-2 expression in esophageal cancer cells (2002) (66)
Salvage therapy of advanced Hodgkin's disease. Critical appraisal of curative potential. (1987) (66)
Molecular cancer prevention: Current status and future directions (2015) (65)
Nucleotide Excision Repair Pathway Genes and Oral Premalignant Lesions (2007) (65)
Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. (2005) (65)
Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. (1998) (65)
Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. (2002) (64)
In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. (2005) (64)
Tumor-infiltrating T-lymphocytes in B-cell diffuse large cell lymphoma related to disease course. (1990) (63)
GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells. (2002) (62)
Novel Susceptibility Loci for Second Primary Tumors/Recurrence in Head and Neck Cancer Patients: Large-Scale Evaluation of Genetic Variants (2009) (62)
Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer (2012) (62)
Correlates of mutagen sensitivity in patients with upper aerodigestive tract cancer. (1997) (62)
Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626. (2008) (62)
THE EVALUATION OF PATIENTS WITH EALES' DISEASE (1983) (62)
Image morphometric nuclear grading of intraepithelial neoplastic lesions with applications to cancer chemoprevention trials. (1999) (62)
Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. (2000) (61)
Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion (2012) (61)
A Prospective Study of Chronic Inflammation in Benign Prostate Tissue and Risk of Prostate Cancer: Linked PCPT and SELECT Cohorts (2017) (61)
A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix. (2001) (61)
Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events. (2011) (60)
Phase I trial of 9-cis retinoic acid in adults with solid tumors. (1996) (60)
An intermittent approach for cancer chemoprevention (2011) (60)
Phase III Prevention Trial of Fenretinide in Patients with Resected Non–Muscle-Invasive Bladder Cancer (2008) (60)
Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma. (1990) (60)
Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. (1995) (60)
MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. (2010) (59)
Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. (2009) (59)
Expression of E-cadherin is associated with squamous differentiation in squamous cell carcinomas. (2000) (59)
Profiling Lipoxygenase Metabolism in Specific Steps of Colorectal Tumorigenesis (2010) (59)
Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-β2 expression (2005) (58)
Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial (2018) (58)
Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions. (2006) (58)
Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma of Both Sexes: Potential Therapeutic Ramifications (2014) (58)
COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer. (2004) (58)
Treatment with HIF-1&agr; Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice (2010) (58)
Interobserver reproducibility of the Lagios nuclear grading system for ductal carcinoma in situ. (1999) (57)
ΔNp63 Overexpression, Alone and in Combination with Other Biomarkers, Predicts the Development of Oral Cancer in Patients with Leukoplakia (2009) (57)
Detection of chromosome instability of tissue fields at risk: In situ hybridization (1996) (57)
Next‐Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma (2018) (57)
Finasteride decreases the risk of prostatic intraepithelial neoplasia. (2007) (56)
Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: toxicities and responses. (1999) (56)
Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers. (2013) (56)
p53 protein accumulation and genomic instability in head and neck multistep tumorigenesis. (2001) (56)
Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma (1997) (56)
Lung cancer chemoprevention: an integrated approach. (2001) (56)
Cost‐effectiveness of prostate cancer chemoprevention (2008) (55)
Effect of age on risk of second primary colorectal cancer. (2001) (55)
Retinoic acid and interferon combination studies in human cancer. (1993) (55)
Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial (2013) (55)
Combined Targeting of the Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways (2005) (54)
Retinoid‐interferon therapy of solid tumors (1997) (54)
Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer (2007) (54)
Cancer prevention by delay. Commentary re: J. A. O'Shaughnessy et al., Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development. Clin. Cancer Res., 8: 314-346, 2002. (2002) (53)
New DNA Methylation Markers and Global DNA Hypomethylation Are Associated with Oral Cancer Development (2015) (53)
Reduced DNA Repair Capacity for Removing Tobacco Carcinogen–Induced DNA Adducts Contributes to Risk of Head and Neck Cancer but not Tumor Characteristics (2010) (53)
Cancer chemoprevention in the 21st century: genetics, risk modeling, and molecular targets. (2000) (53)
Randomized Phase II Trial of Inhaled Budesonide versus Placebo in High-Risk Individuals with CT Screen–Detected Lung Nodules (2010) (52)
Cancer chemoprevention. Part 2: Hormones, nonclassic antioxidant natural agents, NSAIDs, and other agents. (1998) (52)
Leveraging premalignant biology for immune-based cancer prevention (2016) (52)
The non-coding landscape of head and neck squamous cell carcinoma (2016) (52)
Fenretinide Activity in Retinoid-Resistant Oral Leukoplakia (2006) (51)
Increased expression of cytokeratins CK8 and CK19 is associated with head and neck carcinogenesis. (1995) (50)
The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells (2005) (50)
Micronuclei, a biomarker for chemoprevention trials: Results of a randomized study in oral pre‐malignancy (1994) (50)
Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity. (1997) (50)
Cancer Prevention by Delay (2002) (50)
Retinoid chemoprevention studies in upper aerodigestive tract and lung carcinogenesis. (1994) (50)
Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer. (2001) (49)
The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. (2012) (49)
The convergence of cancer prevention and therapy in early-phase clinical drug development. (2004) (49)
Autoimmune hemolytic anemia with reticulocytopenia. A medical emergency. (1980) (49)
Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT) (2005) (49)
Centrosomal abnormality is common in and a potential biomarker for bladder cancer (2003) (49)
Repair Capacity for UV Light–Induced DNA Damage Associated with Risk of Nonmelanoma Skin Cancer and Tumor Progression (2007) (48)
Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case–control study (2011) (48)
Reduction in oral mucosa micronuclei frequency following alpha-tocopherol treatment of oral leukoplakia. (1994) (47)
Akt/mTOR Counteract the Antitumor Activities of Cixutumumab, an Anti-Insulin–like Growth Factor I Receptor Monoclonal Antibody (2011) (47)
Cancer chemoprevention. (1994) (46)
The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members. (2006) (46)
Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize (2016) (46)
Selenium Accumulation in Prostate Tissue During a Randomized, Controlled Short-term Trial of l-Selenomethionine: a Southwest Oncology Group Study (2006) (46)
Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398. (2003) (46)
Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial (2006) (46)
Chemoprevention strategies for the control of cancer (1993) (46)
Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2012) (46)
Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention (2012) (46)
Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells (2009) (45)
Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ‐preservation approach in patients with paranasal sinus carcinoma (2003) (45)
Determination of biomarkers for intermediate end points in chemoprevention trials. (1992) (44)
Serum Signature of Hypoxia-Regulated Factors Is Associated with Progression after Induction Therapy in Head and Neck Squamous Cell Cancer (2010) (44)
MicroRNA-related genetic variants associated with clinical outcomes in early-stage non-small cell lung cancer patients. (2013) (44)
Retinoid chemoprevention of upper aerodigestive tract carcinogenesis. (1992) (44)
The Ability of Bilirubin in Identifying Smokers with Higher Risk of Lung Cancer: A Large Cohort Study in Conjunction with Global Metabolomic Profiling (2014) (44)
APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy (2018) (44)
Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. (1997) (44)
Results of the use of vitamin A and retinoids in cutaneous malignancies. (1989) (44)
The aberrancy of immunophenotype and immunoglobulin status as indicators of prognosis in B cell diffuse large cell lymphoma. (1988) (43)
Design and Progress of a Trial of Selenium to Prevent Prostate Cancer among Men with High-Grade Prostatic Intraepithelial Neoplasia (2006) (43)
MicroRNA Profiling of Salivary Adenoid Cystic Carcinoma: Association of miR-17-92 Upregulation with Poor Outcome (2013) (43)
Epidermal growth factor receptor and K‐Ras mutations and resistance of lung cancer to insulin‐like growth factor 1 receptor tyrosine kinase inhibitors (2012) (43)
Science peels the onion of selenium effects on prostate carcinogenesis. (2004) (43)
Cyclin D1 and Cancer Development in Laryngeal Premalignancy Patients (2009) (43)
Chromosome polysomy and histological characteristics in oral premalignant lesions. (2001) (43)
Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer. (2015) (42)
Quantitative nuclear morphometry by image analysis for prediction of recurrence of ductal carcinoma in situ of the breast. (2001) (42)
Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. (2006) (42)
Does induction chemotherapy have a role in the management of nasopharyngeal carcinoma? Results of treatment in the era of computerized tomography. (1996) (42)
Retinoids in the chemoprevention of bladder cancer (1998) (42)
The Convergent Development of Molecular-Targeted Drugs for Cancer Treatment and Prevention (2007) (42)
Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia. (2002) (42)
Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis. (2002) (41)
Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF- 1R) and insulin receptor (IR) in patients with advanced solid tumors. (2010) (40)
Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway. (2013) (40)
4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer. (2019) (40)
Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies (2019) (40)
Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited. (2005) (39)
Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract. (1998) (39)
Phase II study of Fenretinide (N-[4-Hydroxyphenyl]retinamide) in advanced breast cancer and melanoma (1990) (38)
Human epidermal receptor 2–amplified salivary duct carcinoma: Regression with dual human epidermal receptor 2 inhibition and anti–vascular endothelial growth factor combination treatment (2014) (38)
Nonsurgical Treatments for Skin Cancer: Retinoids and α‐Interferon (1988) (38)
Age-related cataract in men in the selenium and vitamin e cancer prevention trial eye endpoints study: a randomized clinical trial. (2015) (38)
High-Dose Fenretinide in Oral Leukoplakia (2009) (37)
Olfactory neuroblastoma and neuroendocrine carcinoma of the anterior skull base: treatment results at the m.d. Anderson cancer center. (1996) (37)
Bronchial micronuclei as a marker of an early stage of carcinogenesis in the human tracheobronchial epithelium (1990) (36)
Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. (2004) (36)
Modulation of proliferating cell nuclear antigen in the bronchial epithelium of smokers. (2001) (35)
Frontiers in cancer prevention research. (2003) (35)
Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma. (2012) (35)
Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng ml−1, normal DRE and negative for prostate cancer (2015) (34)
Epidemiology, biology, and chemoprevention of aerodigestive cancer (1994) (34)
The Cost of Prostate Cancer Chemoprevention: A Decision Analysis Model (2006) (34)
Steroid levels in cancer of the prostate--markers of tumor differentiation and adequacy of anti-androgen therapy. (1979) (34)
Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells. (2005) (34)
Identification of benzo(a)pyrene diol epoxide-binding DNA fragments using DNA immunoprecipitation technique. (2003) (34)
Identification of retinamides that are more potent than N-(4-hydroxyphenyl)retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells. (2001) (33)
Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. (2011) (33)
Post-transplantation T cell lymphoblastic lymphoma. (1987) (33)
13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial. (1998) (33)
Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions. (2008) (32)
Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors. (1994) (32)
Danazol in the treatment of myelodysplastic syndromes (1987) (32)
Vitamin A derivatives in the prevention and treatment of human cancer. (1988) (31)
Expression of heterogeneous nuclear ribonucleoprotein A2/B1 in bronchial epithelium of chronic smokers. (1998) (31)
Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral premalignant lesion and oral squamous cell carcinoma (2013) (31)
Protease inhibitors in oral carcinogenesis and chemoprevention. (2000) (31)
Cancer prevention: strong science and real medicine. (2005) (31)
Retinoids, neoplasia and differentiation therapy. (1997) (30)
Retinoids as potential chemopreventive agents in squamous cell carcinoma of the head and neck. (1989) (30)
Phase II study of gefitinib in patients with metastatic/recurrent squamous cell carcinoma of the skin. (2006) (30)
Genomic Assessment of Blood-Derived Circulating Tumor DNA in Patients With Colorectal Cancers: Correlation With Tissue Sequencing, Therapeutic Response, and Survival (2019) (30)
Phase II study of 13-cis-retinoic acid plus interferon-alpha 2a in heavily pretreated squamous carcinoma of the cervix. (1995) (29)
Not yet standard: retinoids versus second primary tumors. (1993) (29)
RETRACTED: Molecular based treatment of oral cancer (2003) (29)
Phase I evaluation of all-trans retinoic acid with and without ketoconazole in adults with solid tumors. (1995) (29)
Matrix-Metalloproteinases in Head and Neck Carcinoma–Cancer Genome Atlas Analysis and Fluorescence Imaging in Mice (2014) (29)
The dilemma and promise of cancer chemoprevention (2006) (29)
Chemoprevention strategies for lung and upper aerodigestive tract cancer. (1992) (28)
Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan (2016) (28)
Effect of long-term vitamin E and selenium supplementation on urine F2-isoprostanes, a biomarker of oxidative stress. (2016) (28)
Increased Retinoic Acid Receptor-β4 Correlates In vivo with Reduced Retinoic Acid Receptor-β2 in Esophageal Squamous Cell Carcinoma (2005) (28)
Cigarettes: a smoking gun in cancer chemoprevention. (2005) (27)
Does the level of prostate cancer risk affect cancer prevention with finasteride? (2008) (27)
Phase II study of 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer. (1993) (27)
Shining Light on the COVID-19 Pandemic: A Vitamin D Receptor Checkpoint in Defense of Unregulated Wound Healing (2020) (27)
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck (2002) (27)
Lung cancer chemoprevention. (2000) (27)
Metformin inhibits progression of Head and Neck Squamous Cell Carcinoma by acting Directly on Carcinoma Initiating Cells. (2019) (26)
Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer. (2010) (26)
Peroxisome proliferator-activated receptor-gamma suppresses cyclooxygenase-2 expression in human prostate cells. (2004) (26)
The dynamics of gene expression changes in a mouse model of oral tumorigenesis may help refine prevention and treatment strategies in patients with oral cancer (2016) (26)
Nutritional prevention of cancer: new directions for an increasingly complex challenge. (2009) (26)
Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial (2015) (26)
Elevated Levels of Urinary Prostaglandin E Metabolite Indicate a Poor Prognosis in Ever Smoker Head and Neck Squamous Cell Carcinoma Patients (2009) (26)
AACR White Paper: Shaping the Future of Cancer Prevention – A Roadmap for Advancing Science and Public Health (2018) (26)
Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial. (2011) (26)
Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide. (2000) (26)
Lack of correlation between expression of retinoic acid receptor‐beta and loss of heterozygosity on chromosome band 3p24 in esophageal cancer (2000) (26)
Design considerations for efficient prostate cancer chemoprevention trials. (2001) (25)
Genetic variations in cell‐cycle pathway and the risk of oral premalignant lesions (2008) (25)
Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial (2015) (25)
Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk. (2012) (25)
RRIG1 mediates effects of retinoic acid receptor beta2 on tumor cell growth and gene expression through binding to and inhibition of RhoA. (2006) (25)
Lennert's lymphoma: A clinicopathologic study with emphasis on phenotype and its relationship to survival (1988) (25)
Changes in Serum Proteomic Patterns by Presurgical α-Tocopherol and l-Selenomethionine Supplementation in Prostate Cancer (2005) (25)
15‐Lipoxygenase‐1 transcriptional silencing by DNA methyltransferase‐1 independently of DNA methylation (2008) (25)
Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. (2010) (25)
Sleep and Breathing … and Cancer? (2016) (25)
Can selenium prevent colorectal cancer? A signpost from epidemiology. (2004) (24)
Current status of retinoid chemoprevention of lung cancer. (1995) (24)
Strategies for chemoprevention study of premalignancy and second primary tumors in the head and neck (1995) (24)
Translating Germline Cancer Risk into Precision Prevention (2017) (24)
Smoking status regulates a novel panel of PIWI-interacting RNAs in head and neck squamous cell carcinoma. (2017) (24)
A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck. (1996) (24)
Phase Ib Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Patients with Barrett's Esophagus (2013) (24)
Cyclooxygenase‐2 gene polymorphisms reduce the risk of oral premalignant lesions (2009) (24)
Mitral valve prolapse in sickle cell disease: Manifestation of a generalized connective tissue disorder (1985) (24)
Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide. (2003) (23)
Transition of a Clinical Trial into Translational Research: The Prostate Cancer Prevention Trial Experience (2010) (23)
Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy (2002) (23)
Dominant negative signal transducer and activator of transcription 2 (STAT2) protein: stable expression blocks interferon alpha action in skin squamous cell carcinoma cells. (2003) (23)
15-Lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor γ (2006) (23)
Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial (2015) (23)
p73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. (2001) (23)
13-cis-retinoic acid plus interferon-α2a in recurrent respiratory papillomatosis (1994) (23)
Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. (2010) (22)
Detailed genome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenes of potential clinical significance. (2013) (22)
Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs. (2008) (22)
The paradox of cancer genes in non-malignant conditions: implications for precision medicine (2020) (22)
Mitral valve prolapse in sickle cell disease. Presumptive evidence for a linked connective tissue disorder. (1984) (21)
Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics (2019) (21)
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study (2021) (21)
Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: a phase II randomized trial (1988) (21)
Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. (2014) (21)
Cancer prevention and the American Society of Clinical Oncology. (2004) (21)
Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma. (1995) (21)
Adenoma Recurrences After Resection of Colorectal Carcinoma: Results From the Southwest Oncology Group 9041 Calcium Chemoprevention Pilot Study (2003) (21)
A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN). (2010) (21)
Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2012) (21)
Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma. (2018) (21)
Chemoprevention strategies in lung carcinogenesis. (1993) (21)
Phase III prostate cancer prevention trials: are the costs justified? (2005) (21)
Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the BATTLE Trial (2012) (21)
Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall‐cell lung cancer (2010) (21)
Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations. (2001) (21)
Molecular based treatment of oral cancer. (2003) (20)
Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors. (2016) (20)
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. (2005) (20)
13-cis-retinoic acid and cancer chemoprevention. (1992) (20)
Clonal ambiguity of human immunodeficiency virus-associated lymphomas. Similarity to posttransplant lymphomas. (1988) (20)
Neoplasms of the Head and Neck (2003) (20)
Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer (2018) (20)
Head and Neck Cancer: Emerging Perspectives (2003) (20)
Exercise capacity and cancer-specific quality of life following curative intent treatment of stage I–IIIA lung cancer (2018) (20)
Retinoid chemoprevention of second primary tumors. (1994) (20)
Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions (2021) (19)
Increased leukocyte mitochondrial DNA copy number is associated with oral premalignant lesions: an epidemiology study. (2014) (19)
Paclitaxel-based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinoma: current and future directions. (1999) (19)
Unprecedented Opportunities and Promise for Cancer Prevention Research (2010) (19)
Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial (2017) (19)
Chemoprevention in head and neck cancer. (1991) (19)
The changing face of Phase 1 cancer clinical trials (2009) (19)
Toxicity of isotretinoin in a chemoprevention trial to prevent second primary tumors following head and neck cancer. (1994) (18)
Recent advances in cancer chemoprevention. (1991) (18)
Expression of protein mediators of type I interferon signaling in human squamous cell carcinoma of the skin. (2000) (18)
Ocular toxic effects of fenretinide. (1990) (18)
Pseudoxanthoma elasticum: treatment of gastrointestinal hemorrhage by arterial embolization and observations on autosomal dominant inheritance. (1980) (18)
Computed tomographic findings in orbital Mucor. (1985) (18)
Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial (2013) (18)
Metastatic adenocarcinoma of the endometrium treated with 13‐cis‐retinoic acid plus interferon‐α (1993) (18)
Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). (2006) (17)
Expression and regulation of the ΔN and TAp63 isoforms in salivary gland tumorigenesis clinical and experimental findings. (2011) (17)
Phase I study of paclitaxel, cisplatin, and ifosfamide in patients with recurrent or metastatic squamous cell cancer of the head and neck. (1995) (17)
Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metalloproteinase activity in head and neck carcinoma. (2015) (17)
Chemoprevention of upper aerodigestive tract cancers: A report of the third upper aerodigestive cancer task force workshop (1990) (17)
COX-2 inhibitors and other NSAIDs in bladder and prostate cancer. (2003) (17)
Advanced basal and squamous cell carcinomas of the skin of the head and neck. (1990) (17)
Potential of retinoids in cancer prevention. (1994) (17)
Immune evasion in HPV− head and neck precancer–cancer transition is driven by an aneuploid switch involving chromosome 9p loss (2021) (17)
Loss of Aurora A / STK 15 / BTAK Overexpression Correlates with Transition of in Situ to Invasive Ductal Carcinoma of the Breast (2003) (17)
Micronuclei in bronchial biopsy specimens from heavy smokers: Characterization of an intermediate marker of lung carcinogenesis (1992) (17)
A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers (2016) (17)
Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer (2016) (16)
Efficacy of danazol in pure red cell aplasia (1986) (16)
Co-carcinogenesis and field cancerization: oral lesions offer first signs. (1995) (16)
Agents for Chemoprevention and Their Mechanism of Action (2003) (16)
Chemoprevention of head and neck cancer. (1991) (16)
Cancer chemoprevention and cancer preventive vaccines--a call to action: leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgent need. (2006) (16)
Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial (2018) (16)
Chemoprevention of aerodigestive epithelial cancers. (1992) (16)
Cranial metastases from prostate cancer simulating meningioma: report of two cases and review of the literature. (1986) (15)
Intermediate biomarkers in upper aerodigestive tract and lung chemoprevention trials (1992) (15)
Selenium, genetic variation, and prostate cancer risk: epidemiology reflects back on selenium and vitamin E cancer prevention trial. (2009) (15)
Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia : SWOG S 9917 (2011) (15)
A randomized controlled trial of vitamin E and selenium on rate of decline in lung function (2015) (15)
4-Nitroquinoline-1-oxide-induced mutagen sensitivity and risk of nonmelanoma skin cancer: a case-control analysis. (2007) (15)
Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M.D. Anderson Cancer Center experience. (1997) (15)
Evans' syndrome as a presenting manifestation of atypical paroxysmal cold hemoglobinuria. (1987) (15)
Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology (2015) (15)
p 53 Expression : Predicting Recurrence and Second Primary Tumors in Head and Neck Squamous Cell Carcinoma (1996) (14)
PHASE I/II STUDY OF GEMCITABINE, AN ACTIVE AGENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) (1995) (14)
Effect of 13-cis-retinoic acid on serum prostate-specific antigen levels in patients with recurrent prostate cancer after radical prostatectomy. (2000) (14)
Cloning and characterization of the human retinoid X receptor alpha gene: conservation of structure with the mouse homolog. (2000) (14)
A quantitatively scored cancer-risk assessment tool: its development and use. (1992) (14)
Associations of Serum Sex Steroid Hormone and 5α-Androstane-3α,17β-Diol Glucuronide Concentrations with Prostate Cancer Risk Among Men Treated with Finasteride (2012) (14)
Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) (2005) (14)
Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test (2022) (14)
Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer (2017) (14)
Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with metastatic non-small cell lung cancer (NSCLC) (2007) (13)
Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies (2019) (13)
Human telomerase reverse transcriptase mRNA is highly expressed in normal breast tissues and down-regulated in ductal carcinoma in situ. (2004) (13)
Computed Tomographic Findings (2005) (13)
Primary cancer prevention trials. (2000) (13)
Kinetic monitoring of EGFR T790M in urinary circulating tumor DNA to predict radiographic progression and response in patients with metastatic lung adenocarcinoma. (2015) (13)
Screening at a health fair to identify subjects for an oral leukoplakia chemoprevention trial. (2009) (13)
Current status of chemoprevention of head and neck cancer. (1992) (13)
Identification and characterization of the human retinoid X receptor alpha gene promoter. (2006) (13)
Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer. (2011) (13)
Predictors of Survival in Never-Smokers with Non–Small Cell Lung Cancer: A Large-Scale, Two-Phase Genetic Study (2012) (13)
Mortality in the Randomized, Controlled Lung Intergroup Trial of Isotretinoin (2010) (13)
Aspirin and colorectal cancer prevention in Lynch syndrome (2011) (13)
Phase II study of alpha-interferon and 13-cis-retinoic acid in metastatic melanoma (1993) (13)
Abnormal septal Q waves in sickle cell disease. Prevalence and causative factors. (1985) (13)
Phase II Study of Vinorelbine and Docetaxel in the Treatment of Advanced Non–Small-Cell Lung Cancer as Frontline and Second-Line Therapy (2009) (12)
Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease. (2015) (12)
Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank (2016) (12)
A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors. (1996) (12)
Relationship between tumor size and survival in non-small cell lung cancer (NSCLC): An analysis of the Surveillance, Epidemiology, and End Results (SEER) registry. (2012) (12)
Cranial metastases from prostate cancer simulating meningioma: report of two cases and review of the literature (1986) (12)
A phase II study of interleukin-2 and interferon-alpha in head and neck cancer (1992) (12)
Establishment of Patient-Derived Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response (2021) (12)
Edatrexate improves the antitumor effects of cyclophosphamide and cisplatin against non‐small cell lung cancer (1991) (12)
Telomere Length and Recurrence Risk after Curative Resection in Patients with Early-Stage Non–Small-Cell Lung Cancer: A Prospective Cohort Study (2015) (11)
Improved therapeutic index by leucovorin of edatrexate, cyclophosphamide, and cisplatin regimen for non-small-cell lung cancer. (1992) (11)
Chemoprevention of lung cancer. (1995) (11)
Activation of insulin-like growth factor 1 receptor in patients with non-small cell lung cancer (2015) (11)
Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients (2018) (11)
Phase I evaluation of vandetanib with radiation therapy (RT) ± cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC). (2009) (11)
Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial (2015) (10)
National Cancer Institute--supported cancer chemoprevention research: coming of age. (1999) (10)
Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodology. (2010) (10)
Prediction of Outcome in Diffuse Large Cell Lymphoma by the Major Histocompatibility Complex Class II (HLA-DR, DP, DQ) and Class I (HLA-A, B, C) Phenotype. (1991) (10)
Comment on "Treatment of non-small cell lung cancer stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition)". (2008) (10)
Effect Of Vitamin E And Selenium On Rate Of Decline In FEV1: The Respiratory Ancillary Study To The Selenium And Vitamin E Cancer Prevention Trial (SELECT) (2011) (10)
Computerized image analysis of Ki-67 in ductal breast carcinoma in situ. (2001) (9)
Evolution of aerodigestive tract 13-cis-retinoid acid chemoprevention: the M.D. Anderson experience. (1994) (9)
Phase I study of paclitaxel administered by ten-day continuous infusion (1998) (9)
Cancer Epidemiology, Biomarkers & Prevention, and Cancer Prevention Research: Two Journals, a Common Goal (2008) (9)
Inflammation-related Genetic Variations and Survival for Advanced Non-Small Cell Lung Cancer Receiving First-line Chemotherapy (2014) (9)
Autoimmune Hemolytic Anemia With Reticulocytopenia (2017) (9)
Natural-agent mechanisms and early-phase clinical development. (2013) (9)
HER2-Amplified Salivary Duct Carcinoma: Regression with Dual HER2 Inhibition and Anti-VEGF Combination Treatment (2014) (9)
Phase II trial of 13-cis-retinoic acid plus interferon-α in recurrent head and neck cancer (1993) (8)
Phase II trial of 13-cis-retinoic acid plus interferon-alpha in recurrent head and neck cancer. (1993) (8)
Retinoids in chemoprevention of head and neck carcinogenesis. (1993) (8)
The impact of phosphorylated AMP-activated protein kinase expression on lung cancer survival. (2012) (8)
The efficacy of PlA1-negative platelet transfusion therapy in posttransfusion purpura. (1988) (8)
Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. (1997) (8)
Induction chemotherapy followed by radiotherapy versus radiotherapy alone in patients with advanced nasopharyngeal carcinoma : Results of a matched cohort study (1997) (8)
Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC). (2019) (8)
The future of molecular-targeted cancer chemoprevention. (2008) (8)
Evaluation of Src Tyr419 as a predictive biomarker in a neoadjuvant trial using dasatinib in resectable malignant pleural mesothelioma. (2010) (8)
Randomized placebo-controlled trial (RCT) of erlotinib for prevention of oral cancer (EPOC). (2014) (8)
RESPONSE:Re: Effect of Age on Risk of Second Primary Colorectal Cancer (2002) (8)
Advances in Brief 15-Lipoxygenase-1 Mediates Nonsteroidal Anti-Inflammatory Drug-induced Apoptosis Independently of Cyclooxygenase-2 in Colon Cancer Cells 1 (2000) (8)
Micronuclei: A potential intermediate marker for chemoprevention of aerodigestive tract cancer (1993) (7)
The Ashitaba (Angelica keiskei) Chalcones 4-hydroxyderricin and Xanthoangelol Suppress Melanomagenesis By Targeting BRAF and PI3K (2018) (7)
Phase II study of dasatinib in non-small cell lung cancer (NSCLC). (2009) (7)
Cancer Prevention Research: Back to the Future (2009) (7)
No increased Ki67 expression in ductal carcinoma in situ associated with invasive breast cancer. (2001) (7)
Immune profiling of oral pre-malignant lesions (OPLs): An Erlotinib Prevention of Oral Cancer (EPOC) study biobank analysis. (2017) (7)
Quantitative assessment of cancer risk. (1988) (7)
Chemoprevention as a form of cancer control. (1993) (7)
Effects of curative-intent lung cancer therapy on functional exercise capacity and patient-reported outcomes (2019) (6)
Randomized trial of a short course of erlotinib 150 to 300 mg daily prior to surgery for squamous cell carcinomas of the head and neck (SCCHN) in current, former, and never smokers: Objective responses and clinical outcomes. (2011) (6)
Biology and reversal of aerodigestive tract carcinogenesis. (1995) (6)
ACCELERATED DISCOVERY 15-LOX-1: a Novel Molecular Target of Nonsteroidal Anti-inflammatory Drug-Induced Apoptosis in Colorectal Cancer Cells (2000) (6)
13-Cis-retinoic acid plus interferon-alpha 2a in recurrent respiratory papillomatosis. (1994) (6)
Novel Models of Genetic Education and Testing for Pancreatic Cancer Interception: Preliminary Results from the GENERATE Study (2021) (6)
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer☆ (2016) (6)
Mutations in Human Aggressive and Nonaggressive Basal and Squamous Cell Carcinomas 1 (2003) (6)
Key genes involved in the immune response are generally not associated with intraprostatic inflammation in men without a prostate cancer diagnosis: Results from the prostate cancer prevention trial (2016) (6)
Modulation by 13-cis retinoic acid of biologic markers as indicators of intermediate endpoints in human oral carcinogenesis. (1990) (5)
Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy (RT) with or without cisplatin in locally advanced head and neck squamous cell carcinoma (HNSCC). (2011) (5)
Abstract LB-88: Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination) (2011) (5)
Phase II study of sulofenur (LY 186641). A novel antineoplastic agent in advanced non-small cell lung cancer. (1993) (5)
Phase I studies of gemcitabine (1993) (5)
Chemoprevention of second primary tumours: a model for intervention trials. (1994) (5)
Attrition of Patients on a Precision Oncology Trial: Analysis of the I‐PREDICT Experience (2020) (5)
Nonsurgical treatments for skin cancer: retinoids and alpha-interferon. (1988) (5)
The evaluation of micronuclei as an intermediate endpoint of bronchial carcinogenesis. (1990) (5)
Three-dimensional mRNA measurements reveal minimal regional heterogeneity in esophageal squamous cell carcinoma. (2013) (5)
Phase I/II study of cisplatin, 5-fluorouracil and α-interferon for recurrent carcinoma of the head and neck (2004) (5)
Outcomes study of a course in breast-cancer screening. (2009) (5)
Retinoids and interferons: combination studies in human cancer (2000) (5)
Phase II study of cisplatin, 5-fluorouracil and interferon-alpha in recurrent carcinoma of the cervix. (1995) (5)
913: Results of a Randomized Chemoprevention Trial with Fenretinide in Non-Muscle Invasive Bladder Cancer (2005) (5)
Inaugural issue of Cancer Prevention Research. (2008) (4)
Researchof the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC) (2010) (4)
A Model-Based Cost-Effectiveness Analysis of an Exercise Program for Lung Cancer Survivors After Curative-Intent Treatment (2019) (4)
Phase II study of cisplatin, 5-fluorouracil and interferon-α in recurrent carcinoma of the cervix (2007) (4)
Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study (2019) (4)
Susceptibility and Prevention Δ Np 63 Overexpression , Alone and in Combination with Other Biomarkers , Predicts the Development of Oral Cancer in Patients with Leukoplakia (2009) (4)
Correlation of Src activation with epithelial-mesenchymal transformation and aggressive features of head and neck squamous carcinoma (2007) (4)
p 53 Protein Accumulation and Genomic Instability in Head and Neck Multistep Tumorigenesis 1 (2001) (4)
RARbeta1': primed to fight retinoid resistance in lung carcinogenesis. (2005) (4)
Corrigendum to “American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction” [Gynecol. Oncol. 115 (2009) 132–134] (2010) (4)
PET/CT-guided Involved-field Intensity Modulated Radiation Therapy for Limited-stage Small Cell Lung Cancer (2010) (4)
Erratum: Epidermal growth factor receptor and KRas mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors (Cancer DOI: 10.1002/cncr.26656) (2012) (4)
Retinoid lung cancer prevention. (1994) (3)
Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research. (2007) (3)
Phase I Trial of Weekly Topotecan and Gemcitabine in Patients With Solid Tumors (2009) (3)
Abstract 3821: A prognostic model of head and neck cancer ties TP53 mutation to 3p loss (2014) (3)
A Model-Based Cost-Effectiveness Analysis of an Exercise Program for Lung Cancer Survivors Following Curative-Intent Treatment (2019) (3)
Chronic In fl ammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial (2014) (3)
CHAPTER 20 – Prostate Cancer (2006) (3)
Activation of Protein Kinase G Upregulates Expression of 15-Lipoxygenase-1 in Human Colon Cancer Cells (2005) (3)
Profiling of cytokines and angiogenic factors (C/AF) in head and neck (HN) cancer correlates circulating biomarkers with clinical outcomes following induction chemotherapy (2008) (3)
Phase II study of sulofenur (LY 186641) (1993) (3)
Minimally increased risk of cerebrovascular occlusive disease or intracerebral hemorrhage in patients on bevacizumab treatment and association with intracerebral malignancies (2008) (3)
The effect of 13-cis-retinoic acid chemoprevention on human serum retinol levels. (1998) (3)
Chromatin remodeling (SWI/SNF) complexes, cancer, and response to immunotherapy (2022) (3)
Investigation of PARP1 as a therapeutic target in small cell lung cancer. (2012) (3)
A phase I dose escalation study of pemetrexed in patients with advanced head and neck squamous cell cancer (HNSCC) (2007) (3)
Biomarkers in aerodigestive tract chemoprevention trials (1993) (3)
Advances in Brief Retinoid Receptor-dependent and-independent Effects of N-( 4-Hydroxyphenyl ) retinamide in F 9 Embryonal Carcinoma Cells 1 (1998) (3)
Abstract PL01-03: The landscape of cancer prevention: Personalized approach in lung cancer (2011) (3)
The role of retinoids in preventing second lung cancers (1993) (3)
Proteogenomic analysis of cancer aneuploidy and normal tissues reveals divergent modes of gene regulation across cellular pathways (2022) (3)
Therapeutic implications of cancer gene amplifications without mRNA overexpression: silence may not be golden (2021) (3)
Meta-analysis of the impact of human papillomavirus on cancer risk and overall survival in head and neck squamous cell carcinoma. (2009) (3)
[Treatment of 32 cervico-uterine cancer patients with 13-cis-retinoic acid and interferon alpha]. (1994) (2)
Phase II study of carboplatin and edatrexate (10-EdAM) with leucovorin rescue for patients with recurrent squamous cell carcinoma of the head and neck (2004) (2)
Prevention of nonmelanoma skin cancer. Standard and investigative approaches. (1997) (2)
DNA methyltransferase-3B (DNMT3B) in oral cancer (OC) development. (2011) (2)
Therapeutic Target for Overcoming EGFR Inhibitor Resistance Resistance to EGFR and PI 3 K Inhibitors and Identifies Axl as a Mesenchymal Transition Gene Signature Predicts (2012) (2)
Phase I study of pemetrexed in recurrent/metastatic head and neck squamous cell cancer (HNSCC) and to assess the need for steroid premedication. (2009) (2)
during NSAID-induced Apoptosis in Colorectal Cancer Cells GATA-6 Transcriptional Regulation of 15-Lipoxygenase-1 Updated (2002) (2)
Biologic risk model for recurrence in resected early-stage non-small cell lung cancer (ES NSCLC). (2011) (2)
Evaluating Quality in Clinical Cancer Research: The M.D. Anderson Cancer Center Experience (2008) (2)
Cancer Prevention Research. Letter from the Editor. (2009) (2)
Association of Serum Carotenoids and Retinoids with Intraprostatic Inflammation in Men without Prostate Cancer or Clinical Indication for Biopsy in the Placebo Arm of the Prostate Cancer Prevention Trial (2021) (2)
Phase I/II study of cisplatin, 5-fluorouracil and alpha-interferon for recurrent carcinoma of the head and neck. (1994) (2)
Asymptomatic detection of SARS‐CoV‐2 among cancer patients receiving infusional anti‐cancer therapy (2021) (2)
A non-invasive liquid biopsy approach for therapeutic stratification of lung cancer patients. (2015) (2)
Extrachromosomal DNA in the cancerous transformation of Barrett’s oesophagus (2022) (2)
Accumulation of p53 Protein and Retinoic Acid Receptorin Retinoid (1997) (2)
Retinoids and Interferons as Antiangiogenic Cancer Drugs (1999) (2)
RESULTS OF A PHASE II/III TRIAL OF CELECOXIB TO PREVENT RECURRENCE OF NON-MUSCLE INVASIVE BLADDER CANCER (2009) (2)
Catalyzing Cancer Prevention Research CaPR: A New Year/New Opportunities (2016) (2)
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy (2022) (2)
Longitudinal thumbnail fissures due to erlotinib therapy for lung cancer (2018) (2)
Beta-carotene didn't prevent cancer: what's up doc? (1991) (1)
Targeting mTOR in Head and Neck Cancer—Response (2019) (1)
Intervention approaches in early lung cancer and premalignant disease: breakout group report. (1992) (1)
JAK: Not Just Another Kinase. (2022) (1)
Morphometric Nuclear Grading of Intraepithelial Neoplastic Lesions with Applications to Cancer Chemoprevention Trials 1 (1999) (1)
Short Communication Loss of Aurora A/STK15/BTAK Overexpression Correlates with Transition of in Situ to Invasive Ductal Carcinoma of the Breast (2003) (1)
Predictive Biomarkers and Personalized Medicine Genetic Variants in the PI 3 K / PTEN / AKT / mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor / Recurrence Risk and Response to Retinoid Chemoprevention (2012) (1)
Abstract CN06-02: Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of Polyphenon E in women with a history of hormone receptor-negative breast cancer (2011) (1)
Abstract 5960: Blood-based extracellular vesicle biomarker test for detection of early-stage pancreatic cancer (2022) (1)
Esophageal Cancer Cell Lines Associated with Retinoid Sensitivity and Colony Formation in Is β Expression and Up-Regulation of Retinoic Acid Receptor-Updated Version (1999) (1)
Cancer risk reducing agents (2015) (1)
Intercepting Pancreatic Cancer: Our Dream Team's Resolve to Stop Pancreatic Cancer. (2018) (1)
Phase III PreventionTrial of Fenretinide in Patients with Resected Non ^ Muscle-Invasive Bladder Cancer (2007) (1)
Phase I trial of neoadjuvant dasatinib in patients with resectable malignant pleural mesothelioma. (2009) (1)
13-cis-retinoic acid plus interferon-alpha in solid tumors: keeping the cart behind the horse. (1994) (1)
Retraction notice to 'Molecular based treatment of oral cancer' [Oral Oncol. 39 (2003) 749-758]. (2007) (1)
Abstract 955: Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancer (2011) (1)
Phase III bladder cancer chemoprevention trial with fenretinide. (2006) (1)
Cancer risk reduction counseling: a computer-assisted curriculum. (1991) (1)
Abstract PR-03: Genetic variations in microRNA biogenesis genes as predictors for risk of second primary tumor (SPT) and/or recurrence in patients with early‐stage head and neck cancer (2010) (1)
Improving cascade genetic testing for families with inherited pancreatic cancer (PDAC) risk: The GENetic Education, Risk Assessment and TEsting (GENERATE) study. (2019) (1)
Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy? Subgroup analysis of clinical outcome and toxicity from the BATTLE trial. (2011) (1)
TheAbility of Bilirubin in Identifying Smokerswith Higher Risk of Lung Cancer : A Large Cohort Study in Conjunction with Global Metabolomic Pro fi ling (2014) (1)
Cancer prevention education at the M. D. Anderson Cancer Center. (2009) (1)
Non-steroidal anti-inflammatory drugs and the risk of oral cancer in current and former smokers - [REMOVED] (2005) (1)
Phase II study of carboplatin and continuous infusion bleomycin followed by cisplatin and 5-fluorouracil in recurrent head and neck cancer. (1995) (1)
The Scripps Institution of Oceanography (1959) (1)
A Randomized Clinical Trial of 4-Hydroxyphenylretinamide for High-Grade Squamous Intraepithelial Lesions of the Cervix 1 (2001) (1)
A clinical trial design applying Bayesian adaptive randomization for targeted therapy development in lung cancer: A step toward personalized medicine (2007) (1)
Intermediate end point markers in chemoprevention trials of lung cancer (1997) (1)
Perspectives in Cancer Research Cancer Prevention Science and Practice 1 (2002) (1)
No Increased Ki 67 Expression in Ductal Carcinoma in Situ Associated with Invasive Breast Cancer 1 (2001) (1)
Phase II pilot study of neoadjuvant docetaxel and cisplatin followed by adjuvant erlotinib in patients with stage I-III non-small cell lung cancer (NSCLC). (2009) (1)
Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial? Commentary (2006) (1)
Somatic 9p24.1 alterations in HPV– head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity (2022) (1)
Prognostic factors in early stage head and neck squamous cell carcinoma (HNSCC) patients in a prospective clinical trial (2004) (1)
New DNA methylation markers associated with oral cancer (OC) development (dvlpt). (2012) (1)
Phase II study of 13-cis-retinoic acid and interferon-α2a in patients with advanced squamous cell lung cancer (1993) (1)
Abstract 1675: Lung cancer chemotherapy: genetic variations in the transforming growth factor beta pathway as predictors of survival (2010) (1)
Non-Invasive Monitoring of Urinary KRAS Circulating Tumor DNA for Treatment Response and Minimal Residual Disease in Patients with Lung Adenocarcinoma. (2015) (1)
Combination 13-cis-retinoic acid and interferon alpha-2a in the therapy of solid tumors. (1994) (1)
Abstract 4819: Gene-expression profiles predict sorafenib efficacy in wild-type EGFR non-small cell lung cancer (NSCLC) (2012) (1)
Telomere length and recurrence risk after curative resection in women with adenocarcinoma of the lung: A prospective cohort study. (2013) (1)
Biomarkers: Intermediate endpoints for upper aerodigestive tract chemoprevention trials (1992) (1)
Clinical impact ratings: F ★★★★★✩✩ O ★★★★★✩✩ (2009) (1)
Abstract 4149: Pathway-based serum microRNA profiling and late-stage non-small cell lung cancer survival (2012) (1)
Human papillomavirus (HPV) transmission from oropharyngeal cancer patients to sexual partners. (2010) (1)
Abstract 4985: M4OC-Prevent: Clinical evaluation of metformin for oral cancer precision prevention (2018) (1)
177. In situ analysis of human cervix cancer to 13-cis retinoic acid and alpha interferon (1992) (0)
Letter from the editor. (2012) (0)
Author Correction: Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan (2020) (0)
Deep learning predicts HRD and platinum response from histology slides in breast and ovarian cancer (2023) (0)
Abstract 4109: A 5-gene signature (sig) predicts clinical benefit from erlotinib in non-small cell lung cancer (NSCLC) patients (pts) harboring wild-type (wt) EGFR & KRAS (2011) (0)
L4.1 Evolution of Battle Trials at Md Anderson Cancer Center (2012) (0)
MP4-02 INFLAMMATION IN BENIGN PROSTATE TISSUE AND PROSTATE CANCER IN THE FINASTERIDE ARM OF THE PROSTATE CANCER PREVENTION TRIAL (2015) (0)
Cancer Small Cell Lung − Prognosis in Never Smokers with Non Overexpression : A Feature Associated with Negative Cyclic AMP Response Element-Binding Protein (2008) (0)
Abstract B94: Pharmacogenetics of retinoid chemoprevention in head and neck cancer patients: Modulation of response by common genetic variation in the mTOR signaling pathway (2010) (0)
tigated in 10 families having more than one affected member. (1982) (0)
Merkel cell carcinoma: A second primary tumor following treatment for non- Hodgkin's lymphoma (1995) (0)
Concordance between cancer gene alterations in tumor and circulating tumor DNA correlates with poor survival in a real-world precision-medicine population. (2023) (0)
A double-blind, placebo-controlled,randomized phase II study of celecoxib in patients with oral premalignant lesions (OPL). (2006) (0)
Letter from the Editor (2014) (0)
The association between serum sex steroid hormone concentrations and intraprostatic inflammation in men without prostate cancer and irrespective of clinical indication for biopsy in the placebo arm of the Prostate Cancer Prevention Trial (2020) (0)
An Attenuated Adenovirus , ONYX-015 , As Mouthwash Therapy for Premal ignant (2003) (0)
Introducing Cancer Prevention Research: A Letter from the Editor (2008) (0)
Use of telomere length in peripheral leukocytes to predict risk of recurrence in patients with early-stage non-small cell lung cancer after curative resection. (2010) (0)
Adjuvant Approaches for Preventing Brain Metastases (2008) (0)
Failure of Pretreatment With Intravenous Folic Acid to Alter the Cumulative Hematologic Toxicity (1996) (0)
Food and Drug Administration Center for Drug Evaluation and Research Summary Minutes of the Gastrointestinal Drugs Advisory Committee (2001) (0)
Abstract LB-A07: Clinical utility of genomic assessment of blood-derived circulating tumor (ctDNA) in patients with colorectal cancers (2018) (0)
SerumRetinol andCarotenoidConcentrations and Prostate Cancer Risk : Results from the Prostate Cancer Prevention Trial (2015) (0)
Vitamin E supplementation increased risk for prostate cancer in healthy men at a median of 7 years (2012) (0)
Chapter 59 – Cancer Chemoprevention (2008) (0)
Book Reviews (2000) (0)
58 – Cancer Chemoprevention (2015) (0)
Predictive Biomarkers and Personalized Medicine Comprehensive Biomarker Analysis and Final Ef fi cacy Results of Sorafenib in the BATTLE Trial (2013) (0)
In This Issue (2012) (0)
Abstract 3011: Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma (2018) (0)
Historical Perspective Cancer Prevention Research: Back to the Future (2009) (0)
EGFR Targeted Delivery of Ultrapotent Radiosensitizers for Head and Neck Cancer (2015) (0)
Abstract 5638: Preclinical evidence supporting cotargeting insulin-like growth factor receptor (IGF-1R) and Src in non-small cell lung cancer. (2013) (0)
Abstract 2929: Predictors of survival in never-smokers with non-small cell lung cancer: A large-scale, two-phase genetic study (2012) (0)
Reversal of peneoplastic changes in upper-respiratory epithelium (1992) (0)
Effect Of Vitamin E And Selenium On Incidence Of Physician-Diagnosed COPD: The Selenium And Vitamin E Cancer Prevention Trial (SELECT) (2010) (0)
The Biology Behind Protease Inhibitors in Oral Carcinogenesis and Chemoprevention (2000) (0)
Abstract S09-04: Asymptomatic detection of COVID-19 among cancer patients receiving infusional anti-cancer therapy (2021) (0)
Socio-demographic, Clinical, and Genetic Determinants of Quality of Life in Lung Cancer Patients (2018) (0)
New perspectives on metastatic patterns in lung cancer: The M. D. Anderson thoracic medical oncology database (2007) (0)
Abstract 1274: Associations between genetic polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial (2017) (0)
Phase II study of Fenretinide (N-[4-Hydroxyphenyllretinamide) in advanced breast cancer and melanoma (2001) (0)
John A. Milner: In Memoriam (1947–2013) (2014) (0)
Phase II Clinical Trial of N-( 4-Hydroxyphenyl ) retinamide and Tamoxifen Administration before Definitive Surgery for Breast Neoplasia 1 (2002) (0)
Abstract 4662: Genetic predictors of clinical outcomes for patients with non-small cell lung cancer (2011) (0)
Akt/mammalian target of rapamycin counteract the antitumor activities of cixutumumab an anti-insulin-like growth factor I receptor monoclonal antibody (2011) (0)
Chromosomal fragile site breakage by EBV-encoded EBNA1 at clustered repeats (2023) (0)
Abstract 30: Quantitative monitoring of EGFR mutations in urinary circulating tumor DNA enables non-invasive pharmacodynamic assessment of anti-EGFR drug response (2016) (0)
Abstract B65: Biomarker effects of an oral green tea extract, Polyphenon E, in women with a history of hormone receptor-negative breast cancer (2012) (0)
Deep learning‐based pathology image analysis predicts cancer progression risk in patients with oral leukoplakia (2023) (0)
Prospective Imaging Biomarker Assessment of Mortality Risk in Patients Treated with Head and Neck Radiotherapy (2011) (0)
Assembly and activation of the Hippo signalome by FAT1 tumor suppressor (2018) (0)
Tetracycline-inducible mouse U6 vector for conditional expression of shRNA (2005) (0)
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study (2021) (0)
178. Phase-II trial of 13-cis retinoic acid (13cRA) plus interferon-α (IFN) in locally-advanced squamous cell carcinoma (SCC) of the cervix (1992) (0)
Abstract 1981: MYC downregulation and chemoresistance in non-small cell lung cancer (NSCLC): Evidence from the Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) program (2010) (0)
The paradox of cancer genes in non-malignant conditions: implications for precision medicine (2020) (0)
Cancer prevention and therapy: The molecular interface (2005) (0)
Abstract 2897: Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis (2010) (0)
Diagnosis and staging (2019) (0)
Dietary Patterns and Lung Function: Assessment of the Alternative Health Eating Index‐2010 (AHEI‐2010) and Rate of Change in Forced Expiratory Volume in the First Second (FEV1) (2017) (0)
Conditional inactivation of the mouse SBP2 gene to elucidate the function of selenoproteins in prostate cancer (2007) (0)
Fluorescence Imaging in Mice Cancer Genome Atlas Analysis and − Matrix-Metalloproteinases in Head and Neck Carcinoma (2014) (0)
P h a s e I I a n d B i o logic S tudy o f I nterferon A lfa, R etinoic Acid, a nd C isplatin i n A dvanced S quamous S kin C ancer (2002) (0)
Table 86.7, Occult Lymph Node Metastases for Oral Cavity Carcinoma by Level* (2000) (0)
The changing face of phase I protocols: A closer look at study requirements (2007) (0)
Genetic variants in the telomere maintenance pathway as predictors of second primary tumors and recurrence of early-stage head and neck cancer. (2010) (0)
Spatial PD‐L1, immune‐cell microenvironment, and genomic copy‐number alteration patterns and drivers of invasive‐disease transition in prospective oral precancer cohort (2023) (0)
Abstract 1122: Insulin receptor expression and survival of patients with non-small cell lung cancer (2011) (0)
Skin Squamous Carcinogenesis Progressive Decreases in Nuclear Retinoid Receptors during Updated (2001) (0)
Small Cell Lung Cancer Patients − Outcomes in Early-Stage Non MicroRNA-Related Genetic Variants Associated with Clinical (2013) (0)
Prostate stromal prostaglandin D2 synthase-derived eicosanoid products suppress prostate cancer cell growth (2004) (0)
STK15/BTAK/aurora-A expression in ductal carcinoma in situ of the breast (2001) (0)
KaryoCreate: a new CRISPR-based technology to generate chromosome-specific aneuploidy by targeting human centromeres (2022) (0)
Chemoprevention and Overall Cancer Incidence (2003) (0)
AI-assisted discovery of an ethnicity-influenced driver of cell transformation in esophageal and gastroesophageal junction adenocarcinomas (2022) (0)
Treatment and Prevention of Intraepithelial Neoplasia : An Important Target for Accelerated New Agent Development Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia 1 (2002) (0)
Microenvironment and Immunology CXCR 2 Expression inTumorCells Is aPoorPrognosticFactor and Promotes Invasion and Metastasis in Lung Adenocarcinoma (2013) (0)
Abstract PO-013: Comparison of novel healthcare delivery models on the uptake of genetic education and testing in families with a history of pancreatic cancer: The GENetic Education, Risk Assessment and TEsting (GENERATE) study (2021) (0)
Abstract PL04-04: Vitamin E and selenium for prostate cancer prevention: The SELECT experience (2010) (0)
Cancer Epidemiology, Biomarkers & Prevention and Cancer Prevention Research: Two Journals, a Common Goal (2008) (0)
Abstract 1901: EGFR and K-Ras mutations and resistance of lung cancers to IGF-1R TKI (2012) (0)
Gene expression profiling of oral preneoplastic lesions (OPL) from a prospective prevention trial. (2010) (0)
HER-2/neu Gene Amplification in Ductal Carcinoma In Situ of the Breast 1 (2002) (0)
Results from short-term CT assessments in patients (pts) with advanced poor performance status non-small cell lung cancer (NSCLC) receiving pemetrexed in a phase II trial. (2016) (0)
Role of paclitaxel in the treatment of head and neck cancer. (1994) (0)
Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ–focal adhesion kinase signaling circuitry (2022) (0)
Targeting protein kinase C beta enhances cell death of non-small cell lung cancer cells. (2006) (0)
Positive Surgical Margins in the 10 Most Common Solid Cancers (2018) (0)
Abstract 4127:EGFR and K-Rasmutations and resistance of lung cancer to the IGF-1R tyrosine kinase inhibitors (2010) (0)
1306P Early-stage pancreatic cancer detection using extracellular vesicles (2022) (0)
LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics. (2023) (0)
An A ttenuated A denovirus, O NYX-015, A s M outhwash T herapy for P remalignant O ral D ysplasia (2006) (0)
Retinoids and Cervical Cancer (2020) (0)
Abstract LB-195: A double-blind randomized controlled multisite trial evaluating tissue effects of preoperative finasteride in clinically organ-confined prostate cancer: Pathologic outcomes. (2013) (0)
Retinoic A cid R eceptor-Beta a s a P rognostic I ndicator i n Stage I N on-Small-Cell L ung C ancer (2000) (0)
Retinoids for the Prevention of Cancer (2021) (0)
The incidence of histologic subtypes and b symptoms in long term survival of non surgically treated non small cell lung cancer: P2-186 (2007) (0)
Abstract A3: MicroRNA‐related polymorphisms are associated with clinical outcomes in early stage non‐small cell lung cancer patients (2010) (0)
S10. The cancer prevention-therapy convergence (2008) (0)
Hypoprothrombinemia from coadministration of sulofenur (LY 186641) and warfarin: Report of three cases (1991) (0)
Abstract 4509: Mitochondrial DNA copy number is inversely associated with overall survival in non-small cell lung cancer (2012) (0)
Prognostic factors in early stage head and neck squamous cell carcinoma (HNSCC) patients in a prospective clinical trial. (2004) (0)
Retinoids in Head and Neck Cancer (2020) (0)
Expression β and Is Related to RA Receptor in Vivo Treatment-RA cis Than Binding to Normal Tissue , Increases after 13-Premalignant Oral Lesions , Which Occurs Less Frequently Anti-Retinoic Acid ( RA ) Antibody Binding to Human Updated (2006) (0)
Contribution of the transcriptional factor GATA-6 overexpression to the 15-lipoxygenase-1 transcriptional silencing maintenance in cancer cells (2007) (0)
changes in a mouse model of oral tumorigenesis may help refine prevention and treatment strategies in patients with oral cancer. (2016) (0)
Abstract 879: Mitochondrial DNA content and its association with lung cancer risk and clinical outcomes (2010) (0)
Retinoids as anticancer agents. (1988) (0)
Retinoid chemoprevention of aerodigestive carcinogenesis (1994) (0)
Abstract A029: A randomized study of two Strategies of remote Genetic Education, Risk Assessment, and Testing (GENERATE) for family members of patients with pancreatic cancer (2022) (0)
Abstract A85: Moving to centralized follow‐up from a site‐based model in a large cancer prevention study (2010) (0)
Abstract 4484: A novel objective, image-based phenotypic assay reveals higher α-radiation-induced γ-H2AX level in peripheral blood lymphocytes as a risk predictor for lung cancer (2012) (0)
Associations between genetic polymorphisms and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with paclitaxel-based therapy (2008) (0)
Importance of tumor location and histology in long term survivors (LTS) of non small cell lung cancer (NSCLC) treated without surgery (2008) (0)
Effect Of Vitamin E And Selenium On F2-Isoprostanes, An Oxidative Stress Biomarker, And Lung Function (2012) (0)
Retinol , Carotenoids , and risk of Prostate Cancer 1 Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk : Results from the Prostate Cancer Prevention Trial (2015) (0)
KaryoCreate: A CRISPR-based technology to study chromosome-specific aneuploidy by targeting human centromeres (2023) (0)
Looking Forward to 2013—Saluting the Exceptional Year in 2012 (2013) (0)
Abstract 2249: Use of telomere length and genetic variations in maintenance genes to predict risk of recurrence and survival in patients with early-stage non-small cell lung cancer (2011) (0)
Non-small cell lung cancer (NSCLC) in patients under 50: A long-term follow-up from the M. D. Anderson Cancer Center tumor registry. (2010) (0)
Development of extracellular vesicles-based classifier for detection of early-stage bladder, ovarian, and pancreatic cancer. (2021) (0)
Abstract LB-186: MET receptor tyrosine kinase is a potential novel target for prevention of oral cancer. (2013) (0)
Nonsteroidal Anti-Inflammatory Drugs Induce Apoptosis in Esophageal Cancer Cells by Restoring 15-Lipoxygenase-1 Expression 1 (2001) (0)
3136 Kinetic monitoring of EGFR and KRAS mutations in urinary circulating tumor DNA predicts radiographic progression and response in patients with metastatic lung adenocarcinoma (2015) (0)
Abstract 1728: Genetic variations in epidermal growth factor receptor pathway predict recurrence and response to chemotherapy in early stage non-small cell lung cancer (2012) (0)
Inverse Relationship between 15-Lipoxygenase-2 and PPAR- g Gene Expression in Normal Epithelia Compared with Tumor Epithelia 1 (2005) (0)
Association between human papillomavirus (HPV) status with serum cytokine and angiogenic factor (CAF) profile after induction chemotherapy in head and neck squamous cell carcinoma (HNSCC). (2009) (0)
Cancer, more than a “COVID-19 co-morbidity” (2023) (0)
Retinoids in Skin Cancer (2020) (0)
Comprehensive Landscape of Cyclin Pathway Gene Alterations and Co-occurrence with FGF/FGFR Aberrations Across Urinary Tract Tumors (2022) (0)
Abstract B17: Phase I prevention study of atorvastatin in women at increased risk for breast cancer (2012) (0)
Oral Premalignant Lesions Chromosome Polysomy and Histological Characteristics in Updated (2001) (0)
Phase III trial of adjuvant 13- cis -retinoic acid and interferon-alpha for patients with aggressive skin squamous cell carcinoma. (2006) (0)
Waun Ki Hong (1942-2019) John Mendelsohn (1936-2019). (2019) (0)

This paper list is powered by the following services:

Other Resources About Scott Lippman

en.wikipedia.org

What Schools Are Affiliated With Scott Lippman?

Scott Lippman is affiliated with the following schools:

Scott Lippman's Academic­Influence.com Rankings